Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
– Phase 1b trial will evaluate receptor occupancy of PIPE-791 in the brain and lungs of patients in multiple cohorts using a PET tracer of the LPA1 receptor
– Topline data readout planned for the second quarter of 2025
Excerpt from the Press Release:
SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced dosing of the first cohort of patients in the PIPE-791 Phase 1b positron emission tomography (PET) trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R).
The Phase 1b, open label, single-center trial is expected to measure the correlation of pharmacokinetics to receptor occupancy by PET imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS) patients. Contineum anticipates topline data from the PIPE-791 Phase 1b PET trial in the second quarter of 2025. More information on this trial can be found at https://clinicaltrials.gov (NCT06683612).
“Initiating dosing in this trial brings us closer to a potentially new, first-in-class treatment for IPF and PrMS patients,” said Stephen Huhn, Chief Medical Officer, Contineum Therapeutics. “We expect this trial will establish a pharmacokinetic/pharmacodynamic (PK/PD) link between PIPE-791 and LPA1 receptor occupancy in healthy volunteers, as well as demonstrate target engagement in the disease setting of IPF and PrMS. The results of the Phase 1b PET trial will inform dose selection of our future trials in both indications.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?